Q3 EPS Forecast for Caribou Biosciences Boosted by Analyst

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Analysts at Brookline Capital Management increased their Q3 2025 EPS estimates for shares of Caribou Biosciences in a research report issued on Tuesday, August 12th. Brookline Capital Management analyst L. Cann now forecasts that the company will post earnings per share of ($0.36) for the quarter, up from their previous forecast of ($0.38). The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share. Brookline Capital Management also issued estimates for Caribou Biosciences’ Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.42) EPS, FY2026 earnings at ($0.97) EPS, FY2027 earnings at ($1.41) EPS and FY2028 earnings at $2.02 EPS.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.05. The company had revenue of $2.67 million for the quarter, compared to the consensus estimate of $1.64 million. Caribou Biosciences had a negative net margin of 1,800.93% and a negative return on equity of 62.35%.

Several other brokerages have also recently issued reports on CRBU. Wall Street Zen cut shares of Caribou Biosciences from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright reiterated a “buy” rating and set a $3.00 target price (down from $9.00) on shares of Caribou Biosciences in a report on Monday, April 28th.

Caribou Biosciences Price Performance

Shares of Caribou Biosciences stock opened at $1.98 on Friday. Caribou Biosciences has a 1 year low of $0.66 and a 1 year high of $3.00. The firm’s 50-day moving average is $1.67 and its two-hundred day moving average is $1.25. The stock has a market cap of $184.38 million, a price-to-earnings ratio of -1.11 and a beta of 2.55.

Institutional Trading of Caribou Biosciences

A number of institutional investors have recently modified their holdings of CRBU. JPMorgan Chase & Co. boosted its holdings in shares of Caribou Biosciences by 475.9% in the 4th quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company’s stock valued at $3,969,000 after buying an additional 2,062,563 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in shares of Caribou Biosciences in the 4th quarter valued at about $1,921,000. Cambridge Investment Research Advisors Inc. bought a new stake in shares of Caribou Biosciences in the 1st quarter valued at about $559,000. Aberdeen Group plc boosted its holdings in shares of Caribou Biosciences by 118.3% in the 2nd quarter. Aberdeen Group plc now owns 897,579 shares of the company’s stock valued at $1,131,000 after buying an additional 486,435 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC boosted its holdings in shares of Caribou Biosciences by 28.4% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 2,113,272 shares of the company’s stock valued at $3,360,000 after buying an additional 467,738 shares in the last quarter. 77.51% of the stock is currently owned by institutional investors.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.